Loading
What changed between revision 1 and revision 3, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/gene-doping.md — the filesystem corpus, unchanged. Not an edit.
12.2 kB
Revision 1
Revision 3
lines 7–14 → 7–136 unchanged lines not shown
categories: ["enhancement", "genetics"]categories: ["enhancement", "genetics"]tags: ["sport", "enhancement", "gene therapy", "doping", "detection", "regulation"]tags: ["sport", "enhancement", "gene therapy", "doping", "detection", "regulation"]summary: "The non-therapeutic use of gene transfer or gene regulation to improve athletic performance, prohibited in sport since the early 2000s with no publicly confirmed case."summary: "The non-therapeutic use of gene transfer or gene regulation to improve athletic performance, prohibited in sport since the early 2000s with no publicly confirmed case."updated: "2026-07-27"updated: "2026-10-29"issues: ["The Enhanced Games section, including the 2025 swim claim, carries no citation."]------ ```infobox```infoboxlines 25–94 → 24–17910 unchanged lines not shown
}}`````` **Gene doping** is the use of gene transfer, gene editing or gene regulation to improve athletic performance rather than to treat disease. It has been prohibited in competitive sport since the early 2000s, before any technique for doing it existed, and it remains prohibited today. No case has been publicly confirmed in an elite athlete. The gap between a prohibition written in anticipation and an offence nobody has proved is the defining feature of the subject.**Gene doping** is the use of gene transfer, gene editing or gene regulation to improve athleticperformance rather than to treat disease. It has been prohibited in competitive sport since theearly 2000s, before any technique for doing it existed, and it remains prohibited today. No case hasbeen publicly confirmed in an elite athlete. The subject is defined by that gap between aprohibition written in anticipation and an offence nobody has proved. ## The targets## The targets The candidate genes come from exercise physiology and from muscle-disease research, where the same constructs are studied as therapies.The candidate genes come from exercise physiology and from muscle-disease research, where the sameconstructs are studied as therapies. **Erythropoietin.** EPO drives red-cell production and therefore oxygen delivery. Recombinant EPO is the classic endurance drug; a gene-transfer version would in principle produce it endogenously and continuously. That constancy is also the main hazard, since expression from a viral vector cannot easily be turned down.**Erythropoietin.** EPO drives red-cell production and therefore oxygen delivery. Recombinant EPO isthe classic endurance drug, and a gene-transfer version would in principle produce it endogenouslyand continuously. That constancy is also the main hazard, since expression from a viral vectorcannot easily be turned down. **Myostatin and its antagonists.** Blocking myostatin increases muscle mass, an effect established in cattle, dogs and mice, and pursued clinically for muscle-wasting disease. Follistatin constructs delivered by adeno-associated virus are the most plausible muscle-directed doping agent, for the simple reason that they have been administered to humans outside clinical trials. The biology and its disappointments are set out in [[myostatin-inhibition]].**Myostatin and its antagonists.** Blocking myostatin increases muscle mass, an effect establishedin cattle, dogs and mice, and pursued clinically for muscle-wasting disease. Follistatin constructsdelivered by adeno-associated virus are the most plausible muscle-directed doping agent, becausethey have already been administered to humans outside clinical trials. The biology and itsdisappointments are set out in [[myostatin-inhibition]]. **IGF-1.** Local delivery of insulin-like growth factor 1 by viral vector increased muscle mass and preserved function in aging mice, a result from the late 1990s that gave gene doping its earliest popular image.[^barton1998]**IGF-1.** Local delivery of insulin-like growth factor 1 by viral vector increased muscle mass andpreserved function in aging mice, a result from the late 1990s that gave gene doping its earliestpopular image.[^barton1998] **Metabolic switches.** Transgenic mice overexpressing the nuclear receptor PPARδ in muscle showed a shift toward oxidative fibres and greatly increased running endurance, and pharmacological agonists reproduced part of the effect.[^wang2004] Follow-up work on AMPK and PPARδ agonists framed these compounds as exercise mimetics, and the small molecules involved were added to the prohibited list well before any gene-transfer version was attempted.[^narkar2008]**Metabolic switches.** Transgenic mice overexpressing the nuclear receptor PPARδ in muscle showed ashift toward oxidative fibres and greatly increased running endurance, and pharmacological agonistsreproduced part of the effect.[^wang2004] Follow-up work on AMPK and PPARδ agonists framed thesecompounds as exercise mimetics, and the small molecules involved were added to the prohibited listwell before any gene-transfer version was attempted.[^narkar2008] **Angiogenic and hypoxia pathways.** VEGF and stabilised HIF constructs would increase capillary density or mimic altitude adaptation. These remain conjectural in the doping context.**Angiogenic and hypoxia pathways.** VEGF and stabilised HIF constructs would increase capillarydensity or mimic altitude adaptation. These remain conjectural in the doping context. ## Why it is prohibited## Why it is prohibited The World Anti-Doping Agency lists gene and cell doping as method class M3. The wording is deliberately broad, covering the use of nucleic acid polymers or analogues that alter genome sequences or gene expression by any mechanism, and the use of normal or genetically modified cells.[^wada] The 2018 revision of the list extended the class explicitly to gene-editing agents, which brought [[crispr-cas9]] and its derivatives inside the rule, so an [[epigenome-editing|epigenetic]] intervention that raised expression of a native gene without introducing foreign DNA is prohibited even though it would leave no transgene to find.The World Anti-Doping Agency lists gene and cell doping as method class M3. The wording isdeliberately broad, covering the use of nucleic acid polymers or analogues that alter genomesequences or gene expression by any mechanism, and the use of normal or genetically modifiedcells.[^wada] The 2018 revision of the list extended the class explicitly to gene-editing agents,which brought [[crispr-cas9]] and its derivatives inside the rule. An[[epigenome-editing|epigenetic]] intervention that raised expression of a native gene withoutintroducing foreign DNA is therefore prohibited, even though it would leave no transgene to find. Prohibition rests on the same rationale set out in [[enhancement-in-sport]]: health risk, the integrity of competition, and the coercion of athletes who would otherwise decline. The rule is unusual in one respect. Nearly every other class on the list names substances that exist and are available; M3 anticipates a method, and the anticipated version of it is closer to [[gene-therapy-for-aging]] in its ambitions than to a steroid. Gene transfer sharpens the first of these, because a viral vector cannot be withdrawn. An athlete who over-responds to an EPO construct has no route back short of therapeutic intervention against their own transgene.Prohibition rests on the same rationale set out in [[enhancement-in-sport]]: health risk, theintegrity of competition, and the coercion of athletes who would otherwise decline. The rule isunusual in one respect. Nearly every other class on the list names substances that exist and areavailable, while M3 anticipates a method, one closer in its ambitions to [[gene-therapy-for-aging]]than to a steroid. Gene transfer sharpens the health rationale, because a viral vector cannot bewithdrawn. An athlete who over-responds to an EPO construct has no route back short of therapeuticintervention against their own transgene. ## Detection## Detection Detection strategies fall into three families.Detection strategies fall into three families. - **Direct transgene detection.** A therapeutic construct is usually built from complementary DNA, which lacks the introns present in the genomic copy of the same gene. A polymerase chain reaction assay spanning an exon-exon junction distinguishes the two, and anti-doping laboratories have developed and validated such assays for the leading candidates. The method works well on blood, and less well if the vector was injected into a single muscle and never entered circulation in quantity.- **Direct transgene detection.** A therapeutic construct is usually built from complementary DNA,- **Vector detection.** Residual viral capsid sequences and anti-capsid antibodies persist after administration, which turns [[aav-vectors|pre-existing vector immunity]] into a potential forensic signal. which lacks the introns present in the genomic copy of the same gene. A polymerase chain reaction- **Indirect signatures.** The Athlete Biological Passport tracks haematological and steroidal variables over time and flags deviations from an athlete's own baseline, regardless of cause. Transcriptomic and proteomic signatures of altered gene expression have been proposed as a complementary approach, though establishing the specificity needed for a sanction is difficult. assay spanning an exon-exon junction distinguishes the two. WADA approved the first gene doping test in 2021, and a method published two years later extended the approach to follistatin, growth hormone, growth-hormone-releasing hormone and IGF-1, reporting detection of five transgene copies against a twenty-five-thousand-fold excess of the corresponding native gene.[^baoutina2023] That validation used blood spiked with transgene rather than samples from athletes, and the approach works less well when a vector was injected into a single muscle and never entered circulation in quantity.- **Vector detection.** Residual viral capsid sequences and anti-capsid antibodies persist after administration, which turns [[aav-vectors|pre-existing vector immunity]] into a potential forensic signal.- **Indirect signatures.** The Athlete Biological Passport tracks haematological and steroidal variables over time and flags deviations from an athlete's own baseline, regardless of cause. Transcriptomic and proteomic signatures of altered gene expression have been proposed as a complementary approach, though establishing the specificity needed for a sanction is difficult. > [!caution] Absence of evidence> [!caution] Absence of evidence> No publicly confirmed positive test for gene doping in an elite athlete exists as of 2026. Whether that reflects absence of the practice or the difficulty of catching it is unresolved; anti-doping scientists generally argue both contribute.> No positive test for gene doping in an elite athlete has been publicly reported, more than two> decades after the prohibition and several years after the first approved test entered the> laboratory guidelines. Whether that reflects absence of the practice or the difficulty of catching> it is unresolved, and anti-doping scientists generally argue that both contribute. ## Documented and alleged cases## Documented and alleged cases ```timeline```timeline[[ { "year": "1998", "title": "Muscle gene transfer in mice", "text": "Viral delivery of IGF-1 to mouse muscle increases mass and preserves function with age, and is immediately discussed as a doping risk." }, { "year": "1998", "title": "Muscle gene transfer in mice", "text": "Viral delivery of IGF-1 to mouse muscle increases mass and preserves function with age, and is immediately discussed as a doping risk." }, { "year": "2002–2003", "title": "Anti-doping response", "text": "WADA convenes scientific meetings on gene transfer and adds gene doping to the Prohibited List before any means of doing it is available." }, { "year": "2002-2003", "title": "Anti-doping response", "text": "WADA convenes scientific meetings on gene transfer and adds gene doping to the Prohibited List before any means of doing it is available." }, { "year": "2004", "title": "Endurance transgenics", "text": "Transgenic mice overexpressing PPARδ show large increases in running endurance, producing the 'marathon mouse' framing." }, { "year": "2004", "title": "Endurance transgenics", "text": "Transgenic mice overexpressing PPARδ show large increases in running endurance, producing the 'marathon mouse' framing." }, { "year": "2006", "title": "Repoxygen", "text": "In the trial of German athletics coach Thomas Springstein, correspondence emerges in which he seeks Repoxygen, an experimental EPO gene-therapy construct. No evidence of administration to an athlete is established." }, { "year": "2006", "title": "Repoxygen", "text": "In the trial of German athletics coach Thomas Springstein, correspondence emerges in which he seeks Repoxygen, an experimental EPO gene-therapy construct. No evidence of administration to an athlete is established." }, { "year": "2015–2025", "title": "Unregulated self-administration", "text": "Follistatin gene-transfer products are offered outside clinical trials by companies operating in permissive jurisdictions and taken by self-experimenters, demonstrating that access does not depend on approval." } { "year": "2015-2025", "title": "Unregulated self-administration", "text": "Follistatin gene-transfer products are offered outside clinical trials by companies operating in permissive jurisdictions and taken by self-experimenters, demonstrating that access does not depend on approval." }]]`````` The Repoxygen episode remains the closest thing to a documented attempt, and even there the evidence is of intent rather than of use. The more consequential development has been outside sport altogether: as described in [[biohacking]], gene-transfer products have been sold directly to individuals by companies based in jurisdictions with light regulation, which establishes that an athlete determined to try this would not need a laboratory of their own.The Repoxygen episode remains the closest thing to a documented attempt, and even there the evidenceis of intent rather than of use. The more consequential development has been outside sportaltogether. As described in [[biohacking]], gene-transfer products have been sold directly toindividuals by companies based in jurisdictions with light regulation, which establishes that anathlete determined to try this would not need a laboratory of their own. ## Risks## Risks The safety profile is inherited from [[somatic-gene-therapy]], where it has been characterised in patients who had a disease justifying the risk. Immune responses to the vector and to the transgene product are the dominant hazard; high-dose systemic AAV has caused serious liver injury and deaths in clinical trials for muscle disease. Gene transfer of erythropoietin in macaques produced, in several animals, an immune response that cross-reacted with native erythropoietin and caused severe anaemia, precisely inverting the intended effect.[^gao2004] Insertional mutagenesis is a smaller but real concern with integrating vectors, the genome-level damage catalogued in [[crispr-off-target-effects]] applies to any editing-based version, and uncontrolled expression is a structural problem rather than a dosing error.The safety profile is inherited from [[somatic-gene-therapy]], where it has been characterised inpatients who had a disease justifying the risk. Immune responses to the vector and to the transgeneproduct are the dominant hazard, and high-dose systemic AAV has caused serious liver injury anddeaths in clinical trials for muscle disease. Gene transfer of erythropoietin in macaques produced,in several animals, an immune response that cross-reacted with native erythropoietin and causedsevere anaemia, inverting the intended effect.[^gao2004] Insertional mutagenesis is a smaller butreal concern with integrating vectors, and the genome-level damage catalogued in[[crispr-off-target-effects]] applies to any editing-based version. Uncontrolled expression is astructural problem rather than a dosing error. None of these risks are acceptable in a healthy adult seeking a competitive margin, which is the standard bioethical objection and also the practical reason clinicians decline to provide it. The comparison that anti-doping physicians draw is with [[exercise-and-aging|training itself]], which produces adaptations in the same pathways with a known safety profile and no vector.None of these risks are acceptable in a healthy adult seeking a competitive margin. That is thestandard bioethical objection, and also the practical reason clinicians decline to provide genetransfer. The comparison that anti-doping physicians draw is with[[exercise-and-aging|training itself]], which produces adaptations in the same pathways with a knownsafety profile and no vector. ## The Enhanced Games and the open-doping argument## The Enhanced Games and the open-doping argument The Enhanced Games, announced in 2023 and backed by private investors, proposes competition without anti-doping rules, on the argument that supervised enhancement is safer than the clandestine kind and that records suppressed by prohibition would otherwise be achievable. In 2025 the organisers publicised a swim faster than a long-standing world-record mark, achieved outside sanctioned conditions; world federations rejected the comparison and several moved to bar participants from their events.The Enhanced Games, announced in 2023 and backed by private investors, proposes competition withoutanti-doping rules, on the argument that supervised enhancement is safer than the clandestine kindand that records suppressed by prohibition would otherwise be achievable. In 2025 the organiserspublicised a swim faster than a long-standing world-record mark, achieved outside sanctionedconditions. World federations rejected the comparison, and several moved to bar participants fromtheir events. The first competition was held in Las Vegas in May 2026, across track, swimming andweightlifting, and produced one swim under the standing world-record mark, a result no federationaccepts as a record.[^conversation2026] The venture's stated emphasis has been pharmacological, and its position on gene transfer has been less clearly articulated than its position on drugs. It nonetheless supplies the sharpest version of the argument in [[enhancement-arms-race]]: if a parallel competition removes the rule, the collective-action structure that makes prohibition stable in the first place weakens, and the question of who is protected by the ban becomes concrete. Critics reply that medical supervision does not make an unapproved AAV construct safe, and that the athletes bearing the risk are not the people capitalising the event. The venture is also the clearest current test of whether [[human-enhancement]] can be normalised by staging it in public rather than by arguing for it.The venture's stated emphasis has been pharmacological, and its position on gene transfer has beenless clearly articulated than its position on drugs. It nonetheless supplies the sharpest version ofthe argument in [[enhancement-arms-race]]. If a parallel competition removes the rule, thecollective-action structure that makes prohibition stable weakens, and the question of who isprotected by the ban becomes concrete. Critics reply that medical supervision does not make anunapproved AAV construct safe, that little is established about the long-term effects of combiningseveral enhancement drugs at once,[^conversation2026] and that the athletes bearing the risk are notthe people capitalising the event. The venture is also the clearest current test of whether[[human-enhancement]] can be normalised by staging it in public rather than by arguing for it. ## Outlook## Outlook Two developments would change the picture. The first is the maturation of delivery: as [[lipid-nanoparticles|non-viral delivery]] improves and transient expression becomes routine, a doping agent that clears the body would be far harder to detect than an integrated or episomal transgene that persists. The second is the spread of expression-modulating tools that add no foreign sequence at all, for which the forensic question is not whether a construct is present but whether an athlete's own regulatory state is natural.Two developments would change the picture. The first is the maturation of delivery. As[[lipid-nanoparticles|non-viral delivery]] improves and transient expression becomes routine, adoping agent that clears the body would be far harder to detect than an integrated or episomaltransgene that persists. The second is the spread of expression-modulating tools that add no foreignsequence at all. For those, the forensic question is whether an athlete's own regulatory state isnatural rather than whether a construct is present. Anti-doping science is preparing for both, mainly through longitudinal profiling that looks for anomalous stability or change in an athlete's own biology rather than for a foreign molecule. Whether a sanction can ever be sustained on that basis, against the evidentiary standard arbitration panels apply, has not been tested.Anti-doping science is preparing for both, mainly through longitudinal profiling that looks foranomalous stability or change in an athlete's own biology rather than for a foreign molecule.Whether a sanction can ever be sustained on that basis, against the evidentiary standard arbitrationpanels apply, has not been tested. ## See also## See also lines 108–111 → 193–19813 unchanged lines not shown
[^narkar2008]: `paper` Narkar, V. A. et al. "AMPK and PPARδ agonists are exercise mimetics." *Cell*, 2008. {The compounds were given to mice; GW1516 was never approved for any human use, and anti-doping authorities have since warned athletes about its toxicity in animal studies.}[^narkar2008]: `paper` Narkar, V. A. et al. "AMPK and PPARδ agonists are exercise mimetics." *Cell*, 2008. {The compounds were given to mice; GW1516 was never approved for any human use, and anti-doping authorities have since warned athletes about its toxicity in animal studies.}[^wada]: `regulator` World Anti-Doping Agency. *The Prohibited List*, section M3: Gene and Cell Doping. Published annually. {The list is reissued each January, so the class wording cited here is the current text rather than the original from the early 2000s.}[^wada]: `regulator` World Anti-Doping Agency. *The Prohibited List*, section M3: Gene and Cell Doping. Published annually. {The list is reissued each January, so the class wording cited here is the current text rather than the original from the early 2000s.}[^gao2004]: `paper` Gao, G. et al. "Erythropoietin gene therapy leads to autoimmune anemia in macaques." *Blood*, 2004.[^gao2004]: `paper` Gao, G. et al. "Erythropoietin gene therapy leads to autoimmune anemia in macaques." *Blood*, 2004.[^baoutina2023]: `paper` Baoutina, A., Bhat, S., Li, D.K. and Emslie, K.R. "Towards a robust test to detect gene doping for anabolic enhancement in human athletes." *Drug Testing and Analysis*, 2023. {Validated on blood from eight donors spiked with transgene, not on samples from athletes; it reports what the assay can detect, not that anything was detected.}[^conversation2026]: `news` Thurston, A. and Dowling, M. "We watched the first Enhanced Games live in Las Vegas – this is what we learned." *The Conversation*, 4 June 2026. {A first-hand account of the event by two sport-management academics; it reports what took place and the athletes' own statements, and measures nothing.} removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
87 lines are the same in both revisions, and 29 of them are not shown. Neither revision here is necessarily the current article — read Gene doping for the text this wiki stands behind today.